PixarBio Corporation’s NeuroRelease A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan As Global VP Of Sales & Marketing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation inventors of NeuroRelease, a 14 day non-addictive post-surgical pain treatment with expected FDA approval in 2018, announced today the appointment of David Kaplan as Vice President of Global Sales and Marketing.

David joins PixarBio from Pacira Pharmaceuticals where he was Vice President of Sales, responsible for US sales and for leading the successful relaunch of post-op pain drug Exparel.